D L Carlson Investment Group Inc. Has $2.77 Million Holdings in Kenvue Inc. (NYSE:KVUE)

D L Carlson Investment Group Inc. cut its stake in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 21.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 128,721 shares of the company’s stock after selling 34,320 shares during the period. D L Carlson Investment Group Inc.’s holdings in Kenvue were worth $2,771,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in KVUE. Clearstead Advisors LLC purchased a new position in shares of Kenvue during the 3rd quarter valued at $25,000. Planned Solutions Inc. acquired a new position in Kenvue in the 4th quarter worth about $27,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Kenvue during the 4th quarter worth about $28,000. CVA Family Office LLC bought a new stake in shares of Kenvue in the 4th quarter valued at approximately $32,000. Finally, Hollencrest Capital Management bought a new stake in shares of Kenvue in the 3rd quarter valued at approximately $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 0.2 %

NYSE KVUE traded down $0.03 on Friday, reaching $18.00. The company had a trading volume of 9,421,189 shares, compared to its average volume of 18,841,691. Kenvue Inc. has a 52 week low of $17.75 and a 52 week high of $26.74. The stock’s 50 day moving average is $19.44 and its 200-day moving average is $20.12. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. The stock has a market cap of $34.47 billion and a price-to-earnings ratio of 23.11.

Kenvue (NYSE:KVUEGet Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm’s quarterly revenue was down 24.9% compared to the same quarter last year. Equities analysts predict that Kenvue Inc. will post 1.18 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.44%. The ex-dividend date of this dividend was Tuesday, May 7th. Kenvue’s dividend payout ratio is currently 102.56%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on KVUE. HSBC lifted their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. Sanford C. Bernstein began coverage on shares of Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective for the company. William Blair initiated coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating for the company. The Goldman Sachs Group initiated coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Finally, Citigroup reissued a “neutral” rating and issued a $21.00 price objective on shares of Kenvue in a research note on Tuesday, May 28th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $23.09.

View Our Latest Stock Report on KVUE

Kenvue Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Further Reading

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.